Search for: "Kaisa v. Chang" Results 1 - 20 of 43
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
On 17 April 2024, the Court of Appeal of the UPC handed down its decision concerning the language of proceedings in the (undoubtedly ground-breaking) case of Curio Bioscience v 10x Genomics. [read post]
1 Feb 2022, 7:01 am by Laurence Lai (Simmons & Simmons LLP)
Honourable mentions F-V, 3.2.4 – new example of lack of unity in claims with multiple dependencies. [read post]
14 Nov 2023, 4:18 am by Chloe Dickson (Bristows)
  The IQOS ILUMA’s use of the Curie point or having the heater in the consumable did not change the way in which this result was achieved. [read post]
22 May 2024, 1:15 am by Charlie French (Bristows)
The latest decision may be an indicator that the tide is beginning to change on document access requests in the UPC following the Court of Appeal decision in Ocado v AutoStore, at least in the context of revocation actions. [read post]
27 Mar 2023, 8:18 am by Nicholas Round (Bristows)
On 16 March 2023, the High Court of England and Wales handed down its judgment following the FRAND trial in InterDigital v Lenovo. [read post]
21 Jul 2022, 8:20 am by Brian Cordery (Bristows)
The law in this regard was summarised by Arnold J in Jarden Consumer Solutions (Europe) Ltd v SEB SA [2014] EWHC 445 (Pat) at [103]: “[103] As Kitchin LJ and Sir Robin Jacob said in their joint judgment in Gedeon  Richter plc v Bayer Pharma AG[2012] EWCA Civ 235, [2013] Bus LR D17 at [61], ‘it is trite law that… the older (from the priority date of a patent under attack) a piece of prior art said to render a patent obvious, the harder it is to show… [read post]
The judge reviewed the national case law on selections/deletions from multiple lists (Merck v Shionogi [2016] EWHC 2989 (Pat), Nokia v IPCom [2012] EWCA Civ 567 and GlaxoSmithKline v Wyeth [2016] EWHC 1045 (Pat)) and the EPO cases reviewed therein and in the EPO Case Law Book. [read post]
6 Feb 2024, 7:17 am by Brian Cordery (Bristows)
Was it the intention of the legislators to permit patentees the ability to so change the fundamental nature of a European Patent and retrospectively? [read post]
Does there need to be legislative change to address the role of Artificial Intelligence in the Australian patents scheme? [read post]
On December 10, 2024, the BRPTO issued Ordinance INPI/PR Nº 48 of November 29, 2024, initiating Phase V of the Patent Prosecution Highway (PPH) program. [read post]
4 Aug 2014, 4:35 am
” and “Do Oral Proceedings ever change the outcome? [read post]
10 May 2024, 2:30 am by Brian Cordery (Bristows)
  This approach is said to reduce the risk of the expert giving their views with hindsight but in practice it is not always possible because for instance the cited prior art might change quite late in the case. [read post]
., (v) Meiji Seika Pharma Co., Ltd. and (vi) Ohara … Continue reading against a medical use patent of Otsuka Pharmaceutical Co., Ltd. [read post]
As an example, it can be a sign of infringement if the marketing strategy induces doctors to prescribe the generic for the omitted therapeutic indication (GlaxoSmithKline v. [read post]
16 Jan 2024, 2:22 am by Eden Winlow (Bristows)
We are also sensitive to concerns that unilateral change now, risks being counterproductive. [read post]